Dimensional Fund Advisors LP Increases Position in Achillion Pharmaceuticals, Inc. (ACHN)

Share on StockTwits

Dimensional Fund Advisors LP boosted its holdings in shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) by 3.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,442,477 shares of the biopharmaceutical company’s stock after acquiring an additional 259,762 shares during the period. Dimensional Fund Advisors LP owned 5.37% of Achillion Pharmaceuticals worth $11,833,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. JPMorgan Chase & Co. lifted its position in shares of Achillion Pharmaceuticals by 7.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,039,438 shares of the biopharmaceutical company’s stock worth $3,825,000 after buying an additional 69,270 shares during the last quarter. BlackRock Inc. lifted its position in shares of Achillion Pharmaceuticals by 0.5% during the 3rd quarter. BlackRock Inc. now owns 11,925,359 shares of the biopharmaceutical company’s stock worth $43,885,000 after buying an additional 61,683 shares during the last quarter. Point72 Asset Management L.P. bought a new stake in shares of Achillion Pharmaceuticals during the 3rd quarter worth $6,609,000. MetLife Investment Advisors LLC lifted its position in shares of Achillion Pharmaceuticals by 81.0% during the 3rd quarter. MetLife Investment Advisors LLC now owns 101,528 shares of the biopharmaceutical company’s stock worth $374,000 after buying an additional 45,425 shares during the last quarter. Finally, Teachers Advisors LLC lifted its position in shares of Achillion Pharmaceuticals by 1.3% during the 3rd quarter. Teachers Advisors LLC now owns 1,756,443 shares of the biopharmaceutical company’s stock worth $6,464,000 after buying an additional 22,478 shares during the last quarter. 74.38% of the stock is owned by institutional investors.

Achillion Pharmaceuticals stock opened at $2.93 on Friday. The stock has a market capitalization of $406.44 million, a price-to-earnings ratio of -5.75 and a beta of 2.47. Achillion Pharmaceuticals, Inc. has a 12 month low of $1.29 and a 12 month high of $3.98.

Achillion Pharmaceuticals (NASDAQ:ACHN) last posted its earnings results on Thursday, March 7th. The biopharmaceutical company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.03. On average, equities research analysts anticipate that Achillion Pharmaceuticals, Inc. will post -0.56 EPS for the current fiscal year.

ACHN has been the subject of several research reports. BidaskClub upgraded Achillion Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, February 22nd. Zacks Investment Research upgraded Achillion Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, January 24th. ValuEngine upgraded Achillion Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, January 2nd. Finally, William Blair reiterated an “outperform” rating on shares of Achillion Pharmaceuticals in a research report on Thursday, March 7th. Three research analysts have rated the stock with a hold rating, one has issued a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $4.50.

TRADEMARK VIOLATION WARNING: “Dimensional Fund Advisors LP Increases Position in Achillion Pharmaceuticals, Inc. (ACHN)” was posted by Highlight Press and is the property of of Highlight Press. If you are reading this report on another website, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://highlightpress.com/2019/04/20/dimensional-fund-advisors-lp-increases-position-in-achillion-pharmaceuticals-inc-achn.html.

About Achillion Pharmaceuticals

Achillion Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders. Its lead drug candidate is ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis.

See Also: Call Option

Institutional Ownership by Quarter for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.